Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 187

1.

BRAF targeting sensitizes resistant melanoma to cytotoxic T cells.

Atay C, Kwak T, Lavilla-Alonso S, Donthireddy L, Richards AD, Moberg VE, Pilon-Thomas S, Schell MJ, Messina JL, Rebecca VW, Xiao M, Tan J, Zhang G, Weber JS, Herlyn M, Sarnaik AA, Gabrilovich DI.

Clin Cancer Res. 2019 Feb 14. pii: clincanres.2725.2018. doi: 10.1158/1078-0432.CCR-18-2725. [Epub ahead of print]

PMID:
30765391
2.

Green tea extract for prevention of prostate cancer progression in patients on active surveillance.

Kumar NB, Dickinson SI, Schell MJ, Manley BJ, Poch MA, Pow-Sang J.

Oncotarget. 2018 Dec 28;9(102):37798-37806. doi: 10.18632/oncotarget.26519. eCollection 2018 Dec 28. Review.

3.

Cutaneous Viral Infections Across 2 Anatomic Sites Among a Cohort of Patients Undergoing Skin Cancer Screening.

Rollison DE, Schell MJ, Fenske NA, Cherpelis B, Messina JL, Giuliano AR, Epling-Burnette PK, Hampras SS, Amorrortu RP, Balliu J, Vijayan L, Naqvi SMH, Zhao Y, Parab K, McKay-Chopin S, Gheit T, Tommasino M.

J Infect Dis. 2019 Feb 15;219(5):711-722. doi: 10.1093/infdis/jiy577.

PMID:
30260406
4.

PTPRS Regulates Colorectal Cancer RAS Pathway Activity by Inactivating Erk and Preventing Its Nuclear Translocation.

Davis TB, Yang M, Schell MJ, Wang H, Ma L, Pledger WJ, Yeatman TJ.

Sci Rep. 2018 Jun 18;8(1):9296. doi: 10.1038/s41598-018-27584-x.

5.

Long-term supplementation of decaffeinated green tea extract does not modify body weight or abdominal obesity in a randomized trial of men at high risk for prostate cancer.

Kumar NB, Patel R, Pow-Sang J, Spiess PE, Salup R, Williams CR, Schell MJ.

Oncotarget. 2017 Jun 29;8(58):99093-99103. doi: 10.18632/oncotarget.18858. eCollection 2017 Nov 17.

6.

Tumour radiosensitivity is associated with immune activation in solid tumours.

Strom T, Harrison LB, Giuliano AR, Schell MJ, Eschrich SA, Berglund A, Fulp W, Thapa R, Coppola D, Kim S, Frakes J, Foekens J, Mulé JJ, Torres-Roca JF.

Eur J Cancer. 2017 Oct;84:304-314. doi: 10.1016/j.ejca.2017.08.001. Epub 2017 Aug 29.

7.

Recurrence patterns and associated factors of locoregional failure following neoadjuvant chemoradiation and surgery for esophageal cancer.

Blackham AU, H Naqvi SM, Schell MJ, Jin W, Gangi A, Almhanna K, Fontaine JP, Hoffe SE, Frakes J, Venkat P, Pimiento JM.

J Surg Oncol. 2018 Feb;117(2):150-159. doi: 10.1002/jso.24808. Epub 2017 Aug 22.

PMID:
28833197
8.

SinCHet: a MATLAB toolbox for single cell heterogeneity analysis in cancer.

Li J, Smalley I, Schell MJ, Smalley KSM, Chen YA.

Bioinformatics. 2017 Sep 15;33(18):2951-2953. doi: 10.1093/bioinformatics/btx297.

9.

Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins.

Kumar NB, Pow-Sang J, Spiess PE, Park J, Salup R, Williams CR, Parnes H, Schell MJ.

Oncotarget. 2016 Oct 25;7(43):70794-70802. doi: 10.18632/oncotarget.12222.

10.

A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.

Scott JG, Berglund A, Schell MJ, Mihaylov I, Fulp WJ, Yue B, Welsh E, Caudell JJ, Ahmed K, Strom TS, Mellon E, Venkat P, Johnstone P, Foekens J, Lee J, Moros E, Dalton WS, Eschrich SA, McLeod H, Harrison LB, Torres-Roca JF.

Lancet Oncol. 2017 Feb;18(2):202-211. doi: 10.1016/S1470-2045(16)30648-9. Epub 2016 Dec 18. Erratum in: Lancet Oncol. 2017 Feb;18(2):e65.

PMID:
27993569
11.

Visilizumab with tacrolimus and methotrexate for GvHD prevention after allogeneic hematopoietic cell transplantation from mismatched unrelated donors.

Perez LE, Fernandez H, Ayala E, Beato F, Neuger A, Pidala J, Schell MJ, Anasetti C.

Bone Marrow Transplant. 2017 Apr;52(4):627-629. doi: 10.1038/bmt.2016.330. Epub 2016 Dec 19. No abstract available.

12.

Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer.

Omolo B, Yang M, Lo FY, Schell MJ, Austin S, Howard K, Madan A, Yeatman TJ.

BMC Med Genomics. 2016 Oct 19;9(1):65.

13.

Testing violations of the exponential assumption in cancer clinical trials with survival endpoints.

Han G, Schell MJ, Zhang H, Zelterman D, Pusztai L, Adelson K, Hatzis C.

Biometrics. 2017 Jun;73(2):687-695. doi: 10.1111/biom.12590. Epub 2016 Sep 26.

14.

A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC.

Schell MJ, Yang M, Teer JK, Lo FY, Madan A, Coppola D, Monteiro AN, Nebozhyn MV, Yue B, Loboda A, Bien-Willner GA, Greenawalt DM, Yeatman TJ.

Nat Commun. 2016 Jun 15;7:11743. doi: 10.1038/ncomms11743.

15.

Myosin Vb mediates Cu+ export in polarized hepatocytes.

Gupta A, Schell MJ, Bhattacharjee A, Lutsenko S, Hubbard AL.

J Cell Sci. 2016 Mar 15;129(6):1179-89. doi: 10.1242/jcs.175307. Epub 2016 Jan 28.

16.

Transplanted Neural Progenitor Cells from Distinct Sources Migrate Differentially in an Organotypic Model of Brain Injury.

Ngalula KP, Cramer N, Schell MJ, Juliano SL.

Front Neurol. 2015 Oct 7;6:212. doi: 10.3389/fneur.2015.00212. eCollection 2015.

17.

A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome.

Schell MJ, Yang M, Missiaglia E, Delorenzi M, Soneson C, Yue B, Nebozhyn MV, Loboda A, Bloom G, Yeatman TJ.

Clin Cancer Res. 2016 Feb 1;22(3):734-45. doi: 10.1158/1078-0432.CCR-15-0143. Epub 2015 Oct 7.

18.

Effect of Age on Clinical Outcomes in Phase 1 Trial Participants.

Mahipal A, Denson AC, Djulbegovic B, Lush R, Kumar A, Juan TH, Schell MJ, Sullivan DM.

Cancer Control. 2015 Apr;22(2):235-41.

PMID:
26068771
19.

Both tumor depth and diameter are predictive of sentinel lymph node status and survival in Merkel cell carcinoma.

Smith FO, Yue B, Marzban SS, Walls BL, Carr M, Jackson RS, Puleo CA, Padhya T, Cruse CW, Gonzalez RJ, Sarnaik AA, Schell MJ, DeConti RC, Messina JL, Sondak VK, Zager JS.

Cancer. 2015 Sep 15;121(18):3252-60. doi: 10.1002/cncr.29452. Epub 2015 Jun 2.

20.

Co-evolution of somatic variation in primary and metastatic colorectal cancer may expand biopsy indications in the molecular era.

Kim R, Schell MJ, Teer JK, Greenawalt DM, Yang M, Yeatman TJ.

PLoS One. 2015 May 14;10(5):e0126670. doi: 10.1371/journal.pone.0126670. eCollection 2015.

21.

Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention.

Kumar NB, Pow-Sang J, Egan KM, Spiess PE, Dickinson S, Salup R, Helal M, McLarty J, Williams CR, Schreiber F, Parnes HL, Sebti S, Kazi A, Kang L, Quinn G, Smith T, Yue B, Diaz K, Chornokur G, Crocker T, Schell MJ.

Cancer Prev Res (Phila). 2015 Oct;8(10):879-87. doi: 10.1158/1940-6207.CAPR-14-0324. Epub 2015 Apr 14.

22.

A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.

Gilbert J, Schell MJ, Zhao X, Murphy B, Tanvetyanon T, Leon ME, Neil Hayes D, Haigentz M Jr, Saba N, Nieva J, Bishop J, Sidransky D, Ravi R, Bedi A, Chung CH.

Oral Oncol. 2015 Apr;51(4):376-82. doi: 10.1016/j.oraloncology.2014.12.011. Epub 2015 Jan 13.

23.

Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.

Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh L, Eysmans C, Richards A, Schell MJ, Fisher KJ, Horak CE, Inzunza HD, Yu B, Martinez AJ, Younos I, Weber JS.

Clin Cancer Res. 2015 Feb 15;21(4):712-20. doi: 10.1158/1078-0432.CCR-14-2468. Epub 2014 Dec 18.

24.

Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.

Cives M, Kunz PL, Morse B, Coppola D, Schell MJ, Campos T, Nguyen PT, Nandoskar P, Khandelwal V, Strosberg JR.

Endocr Relat Cancer. 2015 Feb;22(1):1-9. doi: 10.1530/ERC-14-0360. Epub 2014 Nov 6.

25.

Copper directs ATP7B to the apical domain of hepatic cells via basolateral endosomes.

Nyasae LK, Schell MJ, Hubbard AL.

Traffic. 2014 Dec;15(12):1344-65. doi: 10.1111/tra.12229. Epub 2014 Oct 27. Erratum in: Traffic. 2015 Jan;16(1):99.

26.

Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing.

Kothari N, Schell MJ, Teer JK, Yeatman T, Shibata D, Kim R.

J Clin Pathol. 2014 Sep;67(9):764-7.

27.

Phase II multicenter trial of Caphosol for the reduction of mucositis in patients receiving radiation therapy for head and neck cancer.

Rao NG, Trotti A, Kim J, Schell MJ, Zhao X, Amdur RJ, Brizel DM, Chambers MS, Caudell JJ, Miyamoto C, Rosenthal DI.

Oral Oncol. 2014 Aug;50(8):765-9. doi: 10.1016/j.oraloncology.2014.06.001. Epub 2014 Jun 20.

28.

Influence of mindfulness-based stress reduction (MBSR) on telomerase activity in women with breast cancer (BC).

Lengacher CA, Reich RR, Kip KE, Barta M, Ramesar S, Paterson CL, Moscoso MS, Carranza I, Budhrani PH, Kim SJ, Park HY, Jacobsen PB, Schell MJ, Jim HS, Post-White J, Farias JR, Park JY.

Biol Res Nurs. 2014 Oct;16(4):438-47. doi: 10.1177/1099800413519495. Epub 2014 Jan 30.

29.

Baseline immune biomarkers as predictors of MBSR(BC) treatment success in off-treatment breast cancer patients.

Reich RR, Lengacher CA, Kip KE, Shivers SC, Schell MJ, Shelton MM, Widen RH, Newton C, Barta MK, Paterson CL, Farias JR, Cox CE, Klein TW.

Biol Res Nurs. 2014 Oct;16(4):429-37. doi: 10.1177/1099800413519494. Epub 2014 Jan 28.

30.

A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors.

Gray JE, Haura E, Chiappori A, Tanvetyanon T, Williams CC, Pinder-Schenck M, Kish JA, Kreahling J, Lush R, Neuger A, Tetteh L, Akar A, Zhao X, Schell MJ, Bepler G, Altiok S.

Clin Cancer Res. 2014 Mar 15;20(6):1644-55. doi: 10.1158/1078-0432.CCR-13-2235. Epub 2014 Jan 15.

31.

Identifying risk factors using a skin cancer screening program.

Etzkorn JR, Parikh RP, Marzban SS, Law K, Davis AH, Rawal B, Schell MJ, Sondak VK, Messina JL, Rendina LE, Zager JS, Lien MH.

Cancer Control. 2013 Oct;20(4):248-54.

32.

Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma.

Creelan BC, Antonia S, Noyes D, Hunter TB, Simon GR, Bepler G, Williams CC, Tanvetyanon T, Haura EB, Schell MJ, Chiappori A.

J Immunother. 2013 Oct;36(8):442-50. doi: 10.1097/CJI.0b013e3182a80237.

33.

Improved survival modeling in cancer research using a reduced piecewise exponential approach.

Han G, Schell MJ, Kim J.

Stat Med. 2014 Jan 15;33(1):59-73. doi: 10.1002/sim.5915. Epub 2013 Jul 30.

34.

Comparing Two Exponential Distributions Using the Exact Likelihood Ratio Test.

Han G, Schell MJ, Kim J.

Stat Biopharm Res. 2012 Oct 1;4(4):348-356.

35.

Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.

Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR.

J Clin Oncol. 2013 Jul 1;31(19):2404-12. doi: 10.1200/JCO.2012.46.9783. Epub 2013 May 20.

36.

12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?

Messina JL, Fenstermacher DA, Eschrich S, Qu X, Berglund AE, Lloyd MC, Schell MJ, Sondak VK, Weber JS, Mulé JJ.

Sci Rep. 2012;2:765. doi: 10.1038/srep00765. Epub 2012 Oct 24.

37.

Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers.

Gray JE, Altiok S, Alexandrow MG, Walsh FW, Chen J, Schell MJ, Tai DF, Bepler G.

Cancer. 2013 Mar 1;119(5):1023-32. doi: 10.1002/cncr.27836. Epub 2012 Oct 12.

38.

IP3-dependent intracellular Ca2+ release is required for cAMP-induced c-fos expression in hippocampal neurons.

Zhang W, Tingare A, Ng DC, Johnson HW, Schell MJ, Lord RL, Chawla S.

Biochem Biophys Res Commun. 2012 Aug 24;425(2):450-5. doi: 10.1016/j.bbrc.2012.07.122. Epub 2012 Jul 28.

PMID:
22846568
39.

Expression of CXCR4, E-cadherin, Bcl-2, and survivin in Merkel cell carcinoma: an immunohistochemical study using a tissue microarray.

Knapp CF, Sayegh Z, Schell MJ, Rawal B, Ochoa T, Sondak VK, Messina JL.

Am J Dermatopathol. 2012 Aug;34(6):592-6. doi: 10.1097/DAD.0b013e31823e25d3.

40.

A phase II study of RO4929097 in metastatic colorectal cancer.

Strosberg JR, Yeatman T, Weber J, Coppola D, Schell MJ, Han G, Almhanna K, Kim R, Valone T, Jump H, Sullivan D.

Eur J Cancer. 2012 May;48(7):997-1003. doi: 10.1016/j.ejca.2012.02.056. Epub 2012 Mar 23.

41.

A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors.

Strosberg JR, Weber JM, Choi J, Campos TL, Valone TL, Han G, Schell MJ, Kvols LK.

Ann Oncol. 2012 Sep;23(9):2335-41. doi: 10.1093/annonc/mdr614. Epub 2012 Feb 8.

42.

Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.

Simon GR, Schell MJ, Begum M, Kim J, Chiappori A, Haura E, Antonia S, Bepler G.

Cancer. 2012 May 1;118(9):2525-31. doi: 10.1002/cncr.26522. Epub 2011 Oct 25.

43.

ID1 facilitates the growth and metastasis of non-small cell lung cancer in response to nicotinic acetylcholine receptor and epidermal growth factor receptor signaling.

Pillai S, Rizwani W, Li X, Rawal B, Nair S, Schell MJ, Bepler G, Haura E, Coppola D, Chellappan S.

Mol Cell Biol. 2011 Jul;31(14):3052-67. doi: 10.1128/MCB.01311-10. Epub 2011 May 23.

44.

ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis.

Bepler G, Olaussen KA, Vataire AL, Soria JC, Zheng Z, Dunant A, Pignon JP, Schell MJ, Fouret P, Pirker R, Filipits M, Brambilla E.

Am J Pathol. 2011 Jan;178(1):69-78. doi: 10.1016/j.ajpath.2010.11.029. Epub 2010 Dec 23.

45.

Complex cell cycle abnormalities caused by human T-lymphotropic virus type 1 Tax.

Yang L, Kotomura N, Ho YK, Zhi H, Bixler S, Schell MJ, Giam CZ.

J Virol. 2011 Mar;85(6):3001-9. doi: 10.1128/JVI.00086-10. Epub 2011 Jan 5.

46.

Optimism bias leads to inconclusive results-an empirical study.

Djulbegovic B, Kumar A, Magazin A, Schroen AT, Soares H, Hozo I, Clarke M, Sargent D, Schell MJ.

J Clin Epidemiol. 2011 Jun;64(6):583-93. doi: 10.1016/j.jclinepi.2010.09.007. Epub 2010 Dec 16. Review.

47.

Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma.

Mahmood ST, Agresta S, Vigil CE, Zhao X, Han G, D'Amato G, Calitri CE, Dean M, Garrett C, Schell MJ, Antonia S, Chiappori A.

Int J Cancer. 2011 Oct 15;129(8):1963-9. doi: 10.1002/ijc.25843. Epub 2011 Mar 25.

48.

Suicide in patients with pancreatic cancer.

Turaga KK, Malafa MP, Jacobsen PB, Schell MJ, Sarr MG.

Cancer. 2011 Feb 1;117(3):642-7. doi: 10.1002/cncr.25428. Epub 2010 Sep 7.

49.

A femtomole-sensitivity mass assay for inositol hexakisphosphate.

Letcher AJ, Schell MJ, Irvine RF.

Methods Mol Biol. 2010;645:61-71. doi: 10.1007/978-1-60327-175-2_4.

PMID:
20645181
50.

Phosphorylation status of pyruvate dehydrogenase distinguishes metabolic phenotypes of cultured rat brain astrocytes and neurons.

Halim ND, Mcfate T, Mohyeldin A, Okagaki P, Korotchkina LG, Patel MS, Jeoung NH, Harris RA, Schell MJ, Verma A.

Glia. 2010 Aug;58(10):1168-76. doi: 10.1002/glia.20996.

Supplemental Content

Loading ...
Support Center